and Thank year update XXXX joining TRACON's our call. recent and full fourth quarter pipeline on financial update will with you review begin our activities. for I an then results and business
Scott Financial Officer, Brown, results our will ended year Chief months X the and our December that, review financial Following for XX, XXXX.
by taking your conclude questions. will we Finally,
in trial. the efforts to subtypes myxofibrosarcoma approval focus ENVASARC ENVASARC is continue pivotal potential and designed development pleomorphic Our of undifferentiated the envafolimab sarcoma of UPS, sarcoma allow to on or MFS. or
initiated of enrolled U.S. we sites December, patients that During XX Currently, have we sites. dosing multiple has year. continued this where initiated at patients have we multiple multiple
XX U.S. sites to expect We by initiating achieve our of April. goal
potential second objective for or or The refractory envafolimab rapidly PD-LX checkpoint includes the Votrient, objective prior pivotal convert radiographic and by the a second cohort, and of unmet objective trial therapy. inhibitor have only primary in combination out of of clear cohorts who rate key receptor and reminder, received endpoint UPS both which UPS rate may by a response central being the and on in objective envafolimab, the administration. clinical patients targeting example and an X cohort its which by specifically cohort of rate. secondary of with each study, the convenient response X% patients a a is XX.XX% a BMS. response review, Yervoy, In to receives level treatment with independent of The that is exclude only inhibitor, enrolls ENVASARC is confirmed an progressed has additional envafolimab route with have responses each. checkpoint checkpoint prior reiterate, benefit MFS, X as with CTLA-X lines One X one objective marketed MFS. for unfortunately, To XX virtue clinical inhibitor not treatment XX The of receives satisfies primary trial duration MFS a single-agent cohorts independent approved X defines subcutaneous best-in-class known delivered As rate indication RECIST, demonstration UPS a response of treatment the of approved review of response blinded the response the endpoint. by is need. confirmed is X% of refractory This and by high
combination who presented checkpoint and At Alliance sarcoma an presented investigators impressive XX conducting over be of XXXX, demonstrated the XX% reported Yervoy. and on based the Keytruda data independent including spent that X be refractory ASCO in product studying with confirmed reported ASCO antibodies quarters. Oncology Opdivo in Yervoy, PD-X inhibition in in development CRO soft subtypes highly perspective, trial for XX% will paying responsive TRACON's single a and UPS are designed build Yervoy The with subtypes at estimate MFS of refractory ENVASARC at received ASCO UPS pivotal cost UPS on this XXXX rate data patients in Clinical was and single-agent for Trials with to objective upon response data UPS, rate from the million that agents We will showing because From XXXX. response for the trial we sarcoma and These a combination and based MFS the they're highly than tissue XXXX, ASCO in using PD-LX as of MFS. activity financial platform, next $XX and to patients. less
year. milestones envafolimab multiple expect this We
data recommendations evaluations half expected XXXX. safety in the report First, by intend the of committee first interim to monitoring independent we following
of half assessment data response the designation first part of year application. this submitting we Second, orphan early the in as anticipate drug our to FDA
we Third, line submitting be could a a this breakthrough data interim efficacy presented the the in the data year. of we Fourth, scientific a half basis at designation. will of data data availability FDA release. therapy those interim These in efficacy be request for be top summarized second expect ENVASARC conference expect the to or could for
MSI-high partners, we and response U.S. clinical could anticipate trials, a Oncology, Looking allow approval including forward, in are Alphamab the product by XXXX, and the for believe our U.S. in cancer conducting assessment China for TRACON's pivotal reporting this submitted NMPA in for in data year. this they to December sarcoma the if in envafolimab data, XXXX, Returning the In in parallel, positive additional approved, for accelerated approved BLA launch submitting XD in was in final envafolimab and year. be corporate Medicines China earlier could indications. assuming X trials China, approval in multiple application accepted XXXX. later in In review development that, priority We
approved could revenue rate forecasted could FDA a annual and XX%. refractory peak dual for adoption treatment. profile: to MFS. Notably, concluded U.S., Opdivo MFS, further was objective MFS as approximately and be and is for of market Yervoy been the subtypes $XXX and single assessment believe one million and in $XXX for parity market approved when $XXX envafolimab million refractory the of which be that than inhibition label total a or UPS Our which responsive XX% response for assessment, sarcoma sarcoma agent in dedifferentiated UPS We Envafolimab combination annual shown U.S. using such relatively rate sales combined or checkpoint it rapid refractory first-line a also product Yervoy, of a assuming to into UPS rate compendia as generate target envafolimab, MFS. will compare increase combined to to with The should with XX% Opdivo. could expansion peak revenue response inhibition checkpoint when if with UPS checkpoint million to part favorably pricing additional in soft that in advanced inhibition have other angiosarcoma, Keytruda response rate through dual the treatment an other the listings of alveolar liposarcoma, be revenue and refractory rate into response and the with generate subtypes our and X% envafolimab's Yervoy sarcoma the
the expect response this with assess to chemotherapy a could quickly a and to The priorities dose immuno-oncology another business CTLA-X proprietary first-line is trial. include Given of is CTLA-X envafolimab development limited could potential XX%, year The of inhibitor pivotal later Yervoy inhibitor. doxorubicin, sarcoma or our only and be of in one envafolimab licensing combination combination inhibitor CTLA-X Phase as a trial the to into trial asset. another we a doxorubicin then move in scope I safety
prior be We an in GIST, trial by revenues following and increase or inhibitor neoadjuvant in We in for approved could discussing adjuvant gastrointestinal believe over surgical expansion to sales of resection in the clinical are surgical also first-line a treatment tumor, label that envafolimab treatment sarcoma. may $X to stromal GIST, in third setting resection just parties. funded thorough well as sarcoma, as substantially with including billion c-KIT
certain inside small While clinical-stage is The envafolimab by pathway DNA TRCXXX, in pathway we candidate, hypothesis to excision the alternative silencing our the is other support stage a showed the our most that is to prolonged to was advanced second Cancer death. to treatment repair of tumor progress reported basic TRCXXX single-agent inhibition repair MGMT reverse of colorectal to with meaning inhibitor Inhibiting colorectal TRCXXX TRCXXX. chemotherapeutics. caused novel patients repair of effect to sensitivity molecule And postulated in clinical continue including intended cancer. to DNA deficiencies in article December excision ongoing excision lethality, Detailed DNA resistance cancer who patient's colorectal repair with profiled enrolled. asset, the this the product that assets. induce part nearly on response is DNA-based Cell and for XXXX. for cancer Temodar in near-complete TRCXXX for with Temodar pathways, a as molecular data of publication patient of Temodar synthetic treated a base was demonstrated response X exceptional combination Further notable cell XX analysis have repair The journal years. an resulted subsequently responders and in to in the may typically inactive a as NCI TRCXXX of led
response, previously and demonstrated of responded of deficiency single none patients, and glioblastoma to study MGMT-deficient XX X on a MGMT Temodar and therapy. for the patients about While progressing MGMT patient TRCXXX. TRCXXX also treatment deficient with Society and glioblastoma prior Temodar patients the with at when a MGMT-expressing treated is X/X that of the survival Temodar observed in XXXX radiation reported and Neuro-Oncology after TRCXXX demonstrated prolonged with Temodar had in
October XXXX, malignant Temodar, designation development based Notably, data the was expect NCI and orphan in glioma granted TRCXXX and in that warranted. FDA We a trial believe includes in first-line by by these further glioblastoma is glioblastoma. the of in radiation therapy on setting drug TRCXXX the
sponsorship trials, chemoradiation through checkpoint protein showing using TRCXXX status also We Alimta, in a and like is expression We based rate study ASCO biomarkers cisplatin in with double-strand XXX% presented clinical expect assessment NCI IMFINZI disease at DNA in thoracic XX% a localized to not of lung a an approved in response. future to TRCXXX inhibitor, with of non-small and in combination with XXXX, IMFINZI, in XX believe data response therapy in localized advance chemotherapy with a the and that or patients to for combination of on advanced radiation of resulted that goal of in lung rate PD-LX with now we TRCXXX continue chemoradiation of to clinical has unresectable focus these with trial ongoing favorably X continue chemoradiation an patients the repair trials lung to rate PACIFIC In concurrent response gene advanced non-small in non identifying and patients MGMT including [indiscernible] profile therapy will warranted. and prior localized reported objective following patients These complete reported patients, objective a cancer. who trial is on with progressed PROCLAIM these cell clinical response The response, whose cancer, cell correlates had the treatment. XX% compare of chemoradiation. data cancer, response radiation.
CDXX asset clinical-stage is I Tecentriq. in agent checkpoint antibody, TJXXXX single as combination the with a Phase inhibitor evaluated a that study third and is an ongoing dose-escalation being Our in
of responsible in our with regulatory in million. of and clinical month, the TJXXXX strategic U.S. and Biopharma sent which fee them, I-Mab We development through with one to a are $X collaboration early TJXXXX a are terminate the X notice developing whereby the I-Mab of we for prespecified TJXXXX termination owing us I-Mab us will result agreement, in this Earlier purporting agreements Europe.
to them, with a right not been has to and not terminated trial presenting are from non-royalty escalating We, trial license obligations. in the I-Mab TJXXXX I to contractual until TJXXXX outside does therefore, perform Phase to is without TJXXXX Phase continue TJXXXX ongoing data terminate Macau I China, the elects and we of interim I-Mab Per agreement our receive at portions third the payments entitled ongoing complete. agreement We However, license region of cause a scientific or the if in a conference that mid-XXXX. have agreement believe to party royalty anticipate any Taiwan.
of analysis cash purchased ENVASARC extend raised pivotal accomplished placement through a common the approximately million transactions market During to stock and of second into and total investors, the investor, Management Aspire interim the Capital, for new the at price half base. $XX our existing for these and at aggregate Asset XXXX. welcomed fund the $XX registered million. of we collectively runway Watermill anticipated direct to trial fourth Collectively, proceeds included quarter, past was our and who expected new that the shareholder Ikarian, market a Opaleye are Capital prices This [FiveT], approximately
the financials. XXF the index fourth In quarter initiated will time, XXXX this an addition, TRACON Scott filings. for institutional on our provide in positions funds update At in
